Source: BioSpace

Calliditas: Calliditas Therapeutics: Interim Report Q2, 2020

"In June we successfully closed a $90m U.S. IPO on NASDAQ, which including the greenshoe that was exercised in July, resulted in gross proceeds of $97m in total.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Renee Aguiar-Lucander's photo - CEO of Calliditas

CEO

Renee Aguiar-Lucander

CEO Approval Rating

90/100

Calliditas is a pharmaceutical company that develops and commercializes therapeutics for the treatment of inflammatory kidney diseases. Read more